Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.44
-0.12 (-1.26%)
At close: May 16, 2025, 4:00 PM
9.20
-0.24 (-2.54%)
After-hours: May 16, 2025, 7:57 PM EDT
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$108,522
Profits / Employee
-$344,154
Market Cap
431.48M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CAPR News
- 6 hours ago - CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 3 days ago - Capricor Therapeutics, Inc. (CAPR) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 10 days ago - Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewsWire
- 11 days ago - US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
- 11 days ago - Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy - GlobeNewsWire
- 2 months ago - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire